Skip to main content

Table 5 Average cost-effectiveness ratios for cardiovascular disease interventions under multiple scenarios

From: Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis

Intervention description Base-case Undiscounted health benefitsa 10 % coverageb Double costc Lower effectd 50 % effecte
Acute myocardial infarction
 ACE-inhibitor 7526 5626 14,718 7777 26,556 15,172
 Beta-blocker 4054 3031 7926 4191 26,556 8171
 ASA 2398 1792 4685 2480 3545 4831
 Streptokinase 2407 1799 4343 2855 3714 4850
 ASA + clopidogrel 1652 1235 3225 1712 2958 3327
 ASA + streptokinase 1345 1006 2419 1603 2015 2669
 ASA + streptokinase + ACE-inhibitor 1188 888 2133 1411 1903 2342
 Primary PCI 3013 2252 4560 4460 4833 5983
 ASA + streptokinase + ACE-inhibitor + beta-blocker 998 746 1774 1210 1839 1950
 ASA + clopidogrel + PCI 2112 1579 3171 2240 3410 4062
Acute stroke
 ASA 39,896 31,586 75,658 42,135 99,269 79,449
Post-acute myocardial infarction
 ASA 10,345 7701 19,853 11,173 50,593 19,029
 Statin 8822 6552 16,139 10,119 10,659 11,594
 Beta-blocker 5177 3844 9823 5575 7386 10,296
 ACE-inhibitor 4856 3612 9182 5264 6092 6771
 ASA + beta-blocker 3512 2610 6612 3835 6556 6793
 ASA + beta-blocker + statin 2717 2018 4904 3182 4351 4597
 ASA + beta-blocker + statin + ACE-inhibitor 1849 1373 3349 2197 2704 2908
Post-acute stroke
 ACE-inhibitor 3152 2394 5642 3663 3153 3153
 ASA 2822 2121 5065 3264 9996 4833
 Statin 2397 1820 4046 3042 3427 4355
 ASA + statin 1429 1080 2382 1844 2730 2528
 ASA + statin + ACE-inhibitor 1061 803 1751 1386 1616 1545
Primary prevention of IHD and stroke
 Cholesterol lowering treatment for total chol. >6.2 mmol/l 532 293 791 738 605 941
 Cholesterol lowering treatment for total chol. >5.7 mmol/l 557 311 676 888 636 1002
 Anti-hypertension treatment for SBP >160 mmHg 74 42 97 102 77 124
 Combination drug treatment for absolute risk of CVD >35 % 67 39 88 103 69 94
 Anti-hypertension treatment for SBP >140 mmHg 154 88 172 234 161 263
 Combination drug treatment for absolute risk of CVD >25 % 77 45 95 124 80 108
 Combination drug treatment for absolute risk of CVD >15 % 94 55 108 157 98 132
 Combination drug treatment for absolute risk of CVD >5 % 141 82 153 245 148 199
  1. aUndiscounted health benefits
  2. b10 % target coverage
  3. cDouble price for drugs, procedures and laboratory test
  4. dLower boundary of effectiveness estimate
  5. e50 % of point estimate of effectiveness